What Research Does IKA Support on Keratoconus Prevalence and Treatment?

Updated

The International Keratoconus Academy (IKA) supports clinical, translational, and outcomes-based research on corneal ectatic disease, and it uses that research to shape practical clinical recommendations. Its research agenda centers on prevalence studies using Scheimpflug corneal tomography metrics (including a pediatric prevalence study by Harthan et al.), evidence-based treatment algorithms built around corneal cross-linking, and multidisciplinary collaboration to move new science into practice.

What kinds of research IKA supports

IKA describes its research role as supporting clinical, translational, and outcomes-based research that advances the understanding of corneal ectatic disease and improves patient care. Three features define that support:

  • Clinical and outcomes focus — research is framed around what changes patient care, not laboratory science alone.
  • Translation into recommendations — the Academy states it is dedicated to translating emerging scientific evidence into practical clinical recommendations and to establishing consensus on diagnosis and management.
  • A convening role — IKA serves as a forum for developing and disseminating scientific evidence, identifying emerging technologies, and promoting innovation in diagnosis and treatment.

This is a research-and-education mission rather than a single study program. IKA carries it out through scientific meetings, continuing education, webinars, online resources, peer-reviewed publications, and collaborative clinical research.

Prevalence research: Scheimpflug tomography and the pediatric study

IKA's prevalence work is built on Scheimpflug corneal tomography metrics. Two research articles listed by the Academy illustrate the direction:

  • Prevalence of Keratoconus Based on Scheimpflug Corneal Tomography Metrics in a Pediatric Population
  • The Prevalence of Keratoconus Based on Updated Scheimpflug Corneal Tomography Metrics

The pediatric study is attributed to Harthan et al., and IKA states that its pediatric initiative was strengthened by this prevalence study. The choice of Scheimpflug tomography as the measurement basis matters: prevalence estimates depend on which detection criteria are applied, so studies that specify their tomography metrics allow clinicians to compare findings and understand how detection thresholds affect reported rates. The "updated metrics" framing in the second title signals that this is an evolving methodological question rather than a fixed number.

Why the pediatric focus

IKA notes that keratoconus in children is frequently more aggressive and progresses more rapidly than in adults. That clinical observation is the rationale for concentrating prevalence and detection research on children and adolescents, and for pairing it with a screening recommendation (see below).

How research feeds treatment recommendations

IKA's central treatment message is a shift in timing. The Academy has championed a move away from the historical practice of observing patients until disease progression is documented, toward early diagnosis and intervention before irreversible structural damage and vision loss occur.

The mechanism behind this position: corneal cross-linking is intended to preserve vision and reduce the long-term need for corneal transplantation, and its value depends on being applied before structural damage is irreversible. Waiting for documented progression means waiting for damage that treatment can no longer undo. IKA therefore promotes evidence-based treatment algorithms that incorporate cross-linking at the earliest appropriate stage of disease.

A concrete example of how the research and the recommendation connect: a prevalence study showing meaningful keratoconus rates in a pediatric population supports routine risk assessment and advanced imaging in children, which in turn supports earlier cross-linking decisions. The prevalence finding does not by itself set a treatment threshold, but it supplies the case for looking earlier.

What IKA recommends for pediatric screening

Drawing on its pediatric research emphasis, IKA advocates:

  1. Routine risk assessment for children and adolescents at increased risk for ectatic disease.
  2. Advanced corneal imaging in that evaluation, specifically Scheimpflug tomography and Optical Coherence Tomography (OCT).
  3. Timely intervention with corneal cross-linking when early diagnosis is made, to preserve vision during critical years of visual development.

The stated goal of early diagnosis in children is to maximize the opportunity to preserve vision during the years when visual development is still underway — a rationale specific to pediatric patients rather than a general restatement of adult care.

Where to find the research and engage with it

IKA disseminates its work through peer-reviewed publications, scientific meetings, webinars, and online educational resources, and it runs an annual symposium (the 4th Annual IKA Keratoconus Symposium is listed for Saturday, December 12, 2026, in Dallas, Texas, with details at ikasymposium.com). For the prevalence studies themselves, the research article listings on keratoconusacademy.com are the entry point; the Academy's site does not present pricing or access terms for those materials, so check the publication source for availability.

If your interest is clinical practice, the practical takeaway is the pairing IKA emphasizes: use tomography-based detection criteria deliberately, apply them early in pediatric patients with risk factors, and treat the decision to wait for documented progression as the practice the Academy is arguing against.